Illumina Investor Presentation — January 2020

Document content

Francis deSouza |President & CEO |January 13, 20202020 JP Morgan

Healthcare ConferenceSafe Harbor Disclosures

This communication may contain statements that are forward -looking. Forward -looking statements

are subject to known and unknown risks and uncertainties and are based on potentially inaccurate

assumptions that could cause actual results to differ materially from those expected or implied by the

forward -looking statements. Among the important factors that could cause actual results to differ

materially from those in any forward -looking statements are ( i) our ability to further develop and

commercialize our instruments and consumables and to deploy new products, services, and applications,

and expand the markets, for our technology platforms; (ii) our ability to manufacture robust

instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired

technologies, products, or businesses; (iv) our expectations and beliefs regarding future conduct and

growth of the business and the markets in which we operate; (v) challenges inherent in developing,

manufacturing, and launching new products and services; (vi) our expectations regarding obtaining

regulatory approval for our products; (vii) our expectations regarding our future financial results; and (viii)

the application of generally accepted accounting principles, which are highly complex and involve many

subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with

the Securities and Exchange Commission, including our most recent filings on Forms 10 -K and 10 -Q, or in

information disclosed in public conference calls, the date and time of which are released beforehand. We

undertake no obligation, and do not intend, to update these forward -looking statements, to review or

confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current

quarter.$1,861 $2,220 $2,398 $2,752 $3,333 $3,541

2014 2015 2016 2017 2018 2019$Millions~$3,541M

YoY GrowthQ4 2019Preliminary Revenue2020 Guidance

GAAP FY20 EPS Non-GAAP FY20 EPS$6.80 –$7.00$3.86 –$3.93B

FY20 Revenue Guidance Revenue Growth9–11%

Operating Margin~30%2020 Revenue Growth Expected to be 9% to 11%

At the Midpoint of the Guidance Range, Assumptions Include:

●~200K whole genomes for UK Biobank

●~60K whole genomes for NIH’s All of Us

●~20K whole genomes for GeL/UK

Preview truncated — download the full document for the complete content.